retatrutide glucagon receptor vs. Ozempic Retatrutide 40mg Pen | Triple

Despite these advances, several controversies remain unresolved

This is consistent with the glucagon receptor component of the drugs mechanism

However, liraglutide treatment failed to show significant improvement of the UACR and eGFR trajectory in comparison to placebo ( The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) study assessed the CV outcome of liraglutide (1.8 mg) in comparison to placebo (Marso et al., 2016b)

Advertorial Disclosure: This content is promotional in nature and is intended for consumer education regarding a commercially available telehealth service